Abbvie Inc ABBV

$294.55 -0.48 (-0.16%)

Valuation

Market cap
521,499,712,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.95
P/E (forward)
21.06
Profit margin
6.91%
Debt to equity
-17.83

Trading

Volume
4,695,444
Avg volume
4,951,810
Day's range
$293.97 – $301.20
Shares out
1,767,616,000
Stochastic %K
64%
Beta
0.20
Analysts
Moderate Buy
Price target
$309.60

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

phoenixblaze Nov 16, 8:10 PM
$CYDY only green today is $CYDY .$LLY, $ABBV, $AMGN
0 replies
SellasgpsCurativeBAT11 Nov 16, 6:13 PM
$ABBV $BMY $JNJ $PFE $SLS Part 2. "....Michael Anglestein, a senior respiratory biologics sales specialist at AstraZeneca, then turned the conversation to Sellas' galinpepimut-S (GPS). "The REGAL Phase 3 trial for AML is a game changer for CR1 & CR2 patients," Anglestein said. "The trial has been going on for 5 1/2 years with no futility and very few side effects." ..." that GPS and Sellas' other clinical candidate, SLS009, would be "game changers" for AML and potentially other cancers..." Rob Tomko, a medical-device industry executive, agreed. "Going to be an absolute blockbuster once the results come out," Tomko said. "I couldn't agree moreịẠại A Stocktwits user also highlighted a LinkedIn comment attributed to Michael Frascello, a product director at Johnson & Johnson, that appears to have since been deleted. "Agree Sellas GPS and REGAL will be a game changer for AML care," Frascello reportedly said...' ✌️🙏❤️‍🩹
1 replies
SellasgpsCurativeBAT11 Nov 16, 6:00 PM
$SLS $JNJ $PFE $ABBV $BMY Sellas BOD has been working on a BO for almost a year now. I expect an Immediate BO of Sellas after GPS Regal Pivotal Registrational Phase 3 Study Transformative Data. My # 1 Pick is $JNJ Executives have been openly touting Sellas GPS Breakthrough. 2. ABBV Ventoclax will become Obsolete after GPS FDA approval. 3. BMY Onureg will become Obselete after GPS FDA approval. 4. Pfizer CEO Bourla close ties to Sellas CEO Dr. Stergiou and planned focus on Oncology. ✌️🙏❤️‍🩹
1 replies
DidYouReadThis Nov 16, 4:30 PM 0 replies
SGL_FGHI Nov 16, 2:29 PM
$TGTX If this company is not setup for success on any of these points, feel free to share your knowledge-insight. The seven considerations that BP examines and “accepts or balances” before buying: (1) Strategic fit (2) Clinical data integrity and biological differentiation (3) Regulatory alignment and future labeling (4) Chemistry, manufacturing, and controls (5) Intellectual property defensibility (6) Operational continuity and tech transfer (7) Economics – are potential revenues and price feasible-acceptable Example -- TGTX has primary and secondary capacity and to to scale Briumvi IV and for Sub-Q too. This is important for any BP that has patent cliff issues and/or is looking to promptly receive-grow sales, revenues, and profits. $ABBV $AZN $BMY $SNY
1 replies
TruthBroker2 Nov 16, 9:50 AM 1 replies
55X_ROI_Q1_2026 Nov 16, 5:27 AM
$SLS $MRNA $XBI $ABBV Buying Opportunity of a Lifetime. --- OCV501 a Weaker WT1 Peptide Vaccine 5 year Data - the 30% of Patients who Responded had Extended Overall Survival -- Key UNBLINDED Data from the GPS INTERIM ANALYSIS 80% + of GPS P3 Patients Responded. - 80% of Randomly Selected REGAL GPS Patients Showed a Specific T-Cell immune Response, Surpassing the Results From the Previous Phase 2 Study - Note the Top Line Solid Black are Responders / 33% of the trial - GPs P3 Results of 80% + RESPONSE, ALONG 7 PRIOR GPS TRIAL RESULTS, GUARANTEES GPS WILL BE FDA APPROVED and SLS IS WORTH 27X + the CURRENT MARKET PRICE. OCV was a weaker single, HLA Restricted heterclitic WT1 vaccine. IF it had 80% response Like GPS, it would have been FDA Approved and Used in Every Blood Cancer Clinic on the Planet - LIKE GPS WILL BE.
0 replies
Techdamentals Nov 16, 2:19 AM
The S&P 500 rose 2.5% for the week ended Friday, November 13, 2026, and this week brings earnings from Nvidia, Home Depot, Walmart and more. One number from $ABBV's latest report: net revenues rose 10.3% to $17.404 billion in the quarter ended September 30, 2026, from $15.776 billion a year earlier. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/ABBV?ref=st
0 replies